Prescription Price Equity Act of 2000

Summary

Prescription Price Equity Act of 2000 - Amends the Internal Revenue Code to deny, to any taxpayer who is a member of a worldwide affiliated group with any disqualified gross receipts from any developed foreign country, the applicable percentage of the research-related tax benefits. Defines the term "disqualified gross receipts" to mean, with respect to any developed foreign country, gross receipts of the worldwide affiliated group from prescription drugs manufactured or produced by any member of such group and sold for use or consumption in such country if such gross receipts are at least five percent less than the amount which would be such gross receipts were such drugs sold at their respective average manufacturing prices charged by members of such group in the United States. Defines, in addition, the terms "developed foreign country," "applicable percentage," and "research-related tax benefits."

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 15 February 2000

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 15 February 2000

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 15 February 2000

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.